Abstract
Integrase strand transfer inhibitors (INSTI) are therapeutic agents active against both HIV-1 and HIV-2. These drugs are now a preferred drug class for HIV treatment, owing to their virological efficacy, safety and tolerability. Four INSTI are currently approved for use, raltegravir, elvitegravir, dolutegravir and bictegravir. HIV-1 entry inhibitors are less often used but approved agents are maraviroc, a CCR5 receptor antagonist, and enfuvirtide, a fusion inhibitor.
| Original language | English |
|---|---|
| Title of host publication | Encyclopedia of Virology |
| Subtitle of host publication | Volume 1-5, Fourth Edition |
| Publisher | Elsevier |
| Pages | 145-154 |
| Number of pages | 10 |
| Volume | 1-5 |
| ISBN (Electronic) | 9780128145166 |
| DOIs | |
| Publication status | Published - 1 Jan 2020 |
Bibliographical note
Publisher Copyright:© 2021 Elsevier Ltd. All rights reserved
Keywords
- 3TC
- ABC
- Abacavir
- BCRP
- BIC
- Bictegravir
- Breast cancer resistance protein
- CAB
- Cabotegravir
- DTG
- Dolutegravir
- E/c/TAF/FTC
- E/c/TDF/FTC
- Elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine
- Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine
- Emtricitabine
- FTC
- First heptad repeat
- GFR
- Glomerular filtration rate
- HR1
- INSTI
- Integrase strand transfer inhibitor
- Lamivudine
- MATE
- MVC
- Maraviroc
- Multidrug and toxin extrusion transporter
- OCT
- Organic cation transporter
- P-glycoprotein
- P-gp
- PrEP
- Pre exposure prophylaxis
- RAM
- RPV
- Resistance associated mutation
- Rilpivirine
- TAF
- TDF
- Tenofovir alafenamide
- Tenofovir disoproxil fumarate
- UGT
- Uridine diphosphate glucuronosyltransferase
